Some evidence, for example, indicated conflicting results with statin therapy as the therapeutic response to PCSK9 inhibitors seemed to be comparable in FH and polygenic hypercholesterolemia [1, 13]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.